Recent news on Abraxane

Abraxis BioScience to Present at the Bank of America 2007 Health ...  -  May 23, 2007
Business Wire (press release),The first FDA approved product to use this nab platform, ABRAXANE ® , was launched in 2005 for the treatment of metastatic breast cancer.

Abraxis Sees Increased Sales  -  May 10, 2007
TheStreet.comRevenue for chemotherapy drug Abraxane increased to $70.9 million, which included deferred revenue of $9.1 million, compared to $30.3 million in 2006.

Abraxis 1Q Profit Jumps on Sales  -  May 10, 2007
Forbes,Sales of hospital-based products, which include anti-infectives and critical care drugs, rose 24 percent to $140.3 million while sales of Abraxane more than

Cancer patients dig deep to pay for new drugs  -  Apr 26, 2007
Globe and Mail,...“People shouldn't suffer if they don't have to,� said Julia Lelik, a 57-year-old breast-cancer patient who pays to receive Abraxane at the Ottawa Hospital

Abraxis BioScience Founder Awarded Ellis Island Medal of Honor  -  May 15, 2007
dBusinessNews Los Angeles (press release),The first FDA approved product to use this nab platform, ABRAXANE®, was launched in 2005 for the treatment of metastatic breast cancer.

Cancer patients dig deep to pay for new drugs  -  26 Apr 2007
Globe and Mail,...“People shouldn't suffer if they don't have to,� said Julia Lelik, a 57-year-old breast-cancer patient who pays to receive Abraxane at the Ottawa Hospital

Abraxis BioScience, AstraZeneca & Abraxane  -  Apr 18, 2007
Scoop.co.nz,That new drug is called Abraxane and it has pushed Abraxis BioScience stock from $5 in 2002 to $27 in 2007. The lofty stock price has made Abraxis CEO and

Abraxis BioScience Presents Pre-Clinical Findings That Support ...  -  Apr 19, 2007
PharmaLive.com (press release),Abraxis BioScience received approval from the US Food and Drug Administration for ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension)

Tentative OK for Abraxis Drug  -  Apr 19, 2007
Los Angeles Business Journal (subscription),The company already has one brand-name drug on the market, Abraxane, which is FDA-approved as a second-tier treatment for breast cancer.

Analysis: Sanofi's Taxotere keeps top spot  -  Mar 27, 2007
United Press InternationalA nanoparticle formulation of Abraxis/AstraZeneca's Abraxane may also help drive market growth. A phase 2 trial comparing Abraxane to Taxotere in the

Abraxis BioScience Announces Date for First Quarter Financial ...  -  Apr 12, 2007
Genetic Engineering News (press release),The first FDA approved product to use this nab platform, ABRAXANE(R), was launched in 2005 for the treatment of metastatic breast cancer.

Tapestry Pharmaceuticals Presents Data on TPI at the AACR Annual ...  -  Apr 16, 2007
PipelineReview.com (press release),89% tumor growth inhibition, higher than the tumor growth inhibition rates observed for paclitaxel (13%), docetaxel (24%) and Abraxane-- (38%).

Tapestry Pharmaceuticals Presents Data on TPI 287 at the AACR ...  -  Apr 15, 2007
PR-Inside.com (Pressemitteilung),...growth inhibition, higher than the tumor growth inhibition rates observed for paclitaxel (13%), docetaxel (24%) and Abraxane(R) (38%). About TPI 287

Tapestry Pharmaceuticals Presents Data on TPI 287 at the AACR ...  -  Apr 15, 2007
PR Newswire (press release),...(24%) and Abraxane(R) (38%). About TPI 287 TPI 287 is a proprietary next-generation taxane being studied for the treatment of various forms of cancer.

Nano scientists make huge advances  -  Apr 11, 2007
Ninemsn,First-generation nanoparticles (like Abraxane, developed in the US and used in breast cancer treatment) are already available.

Abraxis BioScience to Initiate Two Phase I/II Clinical Trials with ...  -  Mar 21, 2007
PipelineReview.com (press release),..."These data with nab-docetaxel are similar to the comparative pre-clinical data seen with ABRAXANE versus Taxol (paclitaxel), which ultimately proved to be

Abraxis BioScience Reports Record Revenue of $765 Million in 2006 ...  -  Feb 26, 2007
Genetic Engineering News (press release),ABI focuses primarily on the company's internally developed proprietary products including ABRAXANE and its proprietary pipeline.

Woman wins cancer fight  -  Mar 19, 2007
Sun-Sentinel.com,According to the breastcancer.org Web site, the FDA has approved Abraxane as a second-line therapy, after another chemotherapy regimen has been used and has

Williams-Labadie Promotes Susan Choudhry to Senior Account Supervisor  -  Mar 14, 2007
PharmaLive.com (press release),2003 as an Account Executive and she has worked on a number of accounts, including FACTIVE® (Oscient Pharmaceuticals) and ABRAXANE® (Abraxis Oncology).

Abraxis Achieves Record Revenues  -  Feb 26, 2007
Genetic Engineering News (press release),Annual 2006 Abraxane® (paclitaxel protein-bound particles for injectable suspension) revenue increased to $174.9 million versus $133.7 million in 2005.

Abraxis BioScience (ABBI) Reports Q4 Earnings, Comments on FY07  -  Feb 26, 2007
StreetInsider.com (subscription),...excluding product rights amortization associated with the AstraZeneca product purchase; ABRAXANE net sales between $285 million and $305 million;

UPDATE 1-TABLE-Abraxis BioScience Q4 earnings rise  -  Feb 26, 2007
Reuters...--For full year 2007, the company said it expects net sales for its Abraxane cancer drug to be between $285 million and $305 million, versus $174.9 million

ERRATUM: Bevacizumab and Paclitaxel Yield Promising Results in ...  -  Mar 9, 2007
DG News...[Presentation title: Bevacizumab (Avastin) And Albumin Bound Paclitaxel (Abraxane) Treatment In Metastatic Breast Cancer. Abstract 1095]

Cytogen Reports Fourth Quarter and Full Year 2006 Financial Results  -  Mar 1, 2007
PharmaLive.com (press release),...breast cancer through the initiation of a Phase 1 trial evaluating QUADRAMET and albumin-bound paclitaxel (Abraxane(R), Abraxis BioScience, Inc.).

Hero MD: "How do I tell my patient . . .?  -  Feb 10, 2007
Tort Deform,Abraxane (formerly ABI-007) is an old drug in a new package that promises to make chemotherapy less toxic and more effective for women with metastatic

Genta Incorporated Announces Fourth Quarter and Year End 2006 ...  -  Feb 15, 2007
Drug Newswire (press release),The Company also initiated a pilot study that combines Genasense with Abraxane(R) (paclitaxel protein-bound particles for injectable suspension)

Abraxis BioScience Announces Date for Fourth Quarter and Full Year ...  -  Feb 6, 2007
PharmaLive.com (press release),The first FDA approved product to use this nab platform, ABRAXANE(R), was launched in 2005 for the treatment of metastatic breast cancer.

Q4 2006 Genta Earnings Conference Call - Final  -  Feb 20, 2007
Insurance News Net,Can you comment on -- you mentioned the Phase I trial that's ongoing right now in combination with Temodar and Abraxane. And then also, the sub-Q trial.

Pharma Sector: Few Newsmakers Of The Week - Exelixis, MGI Pharma ...  -  Feb 3, 2007
Trading Markets,In December last year, Genta commenced a follow-on study to evaluate the safety and efficacy of Genasense when combined with Abraxis Oncology's Abraxane and

Pharma Sector: Few Newsmakers Of The Week - Opexa, J&J, Glaxo ...  -  Feb 11, 2007
Trading Markets,The new pilot study, which is currently underway, evaluates the safety and efficacy of Genasense when combined with Abraxis Oncology's Abraxane and Schering

Abraxis BioScience Files Marketing Application for Abraxane in ...  -  Jan 17, 2007
PharmaLive.com (press release),This is the second global regulatory filing for ABRAXANE to be accepted for review in the past four months. A marketing authorization application is also

Abraxane® in Combinaton with Xeloda® Effective Against Metastatic ...  -  Jan 2, 2007
Cancer Consultants (press release),According to results recently published at the 2006 annual San Antonio Breast Cancer Symposium, Abraxane® (albumin-bound paclitaxel protein-bound particles

New nanotech anti-cancer drug delivery system introduced  -  Jan 9, 2007
In-PharmaTechnologist.com,The new Nanoxel system would seem to be in competition with Abraxis BioScience's paclitaxel drug, Abraxane, which gained FDA approval in January 2005.

2006: A Mixed Blessing For Midwest Life Science Companies  -  Jan 8, 2007
MidwestBusiness.com,Abraxis Bioscience suffered – in spite of the successful launch of new cancer drug Abraxane – as a result of the merger of publicly traded American

Abraxis BioScience to Present at the JPMorgan Healthcare Conference  -  Jan 5, 2007
PharmaLive.com (press release),The first FDA approved product to use this nab platform, ABRAXANE(R), was launched in 2005 for the treatment of metastatic breast cancer.

Dabur Pharma launches improved cancer drug  -  Jan 4, 2007
Reuters India,Burman said the only other comparable non-cremophor-based version of paclitaxel was the more expensive Abraxane, made and marketed by Abraxis BioScience

Analysis: Stopping breast-cancer return  -  Dec 19, 2006
Science Daily (press release)In another study, the use of a new formulation of paclitaxel, branded as Taxol, called nab-paclitaxel -- which is sold under the trade name Abraxane

Compared to Taxotere®, Abraxane® Improves Response Rates and ...  -  26 Dec 2006
Cancer Consultants (press release),According to results recently published at the 2006 annual San Antonio Breast Cancer Symposium (SABCS), Abraxane (albumin-bound paclitaxel) as initial

Abraxane® Improves Response Rates and Progression-free Survival ...  -  Dec 19, 2006
Cancer Consultants (press release),According to results recently published at the 2006 annual San Antonio Breast Cancer Symposium, Abraxane® (albumin-bound paclitaxel protein-bound particles

SABCS: Abraxane Combination Therapy Effective for Metastatic ...  -  Dec 24, 2006
MedPage Today,17 -- Abraxane, the nanoparticle albumin-bound form of paclitaxel, appears effective against metastatic breast cancer in combination with Xeloda

CORRECTED - Abraxis says Abraxane more effective than Taxotere  -  Dec 17, 2006
ReutersO: Quote, Profile , Research) Abraxane given weekly was more effective for patients with advanced breast cancer than Sanofi-Aventis SA's (SASY.

Abraxis to Initiate Worldwide Head-to-Head Phase III Registration ...  -  Dec 17, 2006
Business Wire (press release),The interim analysis showed that first-line treatment with weekly ABRAXANE (100 and 150 mg/m 2 ) increased tumor response rate by greater than 60 percent

Zoek in het archief  -  Dec 17, 2006
Netherlands Corporate News (persbericht),17, 2006-- Abraxis to Initiate Worldwide Head-to-Head Phase III Registration Trial Comparing ABRAXANE versus Taxotere in First-Line Metastatic Breast Cancer

Genta Initiates Pilot Clinical Trial of Genasense® Plus Abraxane ...  -  Nov 30, 2006
PipelineReview.com (press release),...synergy when Genasense was combined with Abraxane® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) (Abraxis BioScience,

Genta Initiates Pilot Clinical Trial Of Genasense(R) Plus Abraxane ...  -  Nov 30, 2006
Medical News Today (press release),...was combined with Abraxane(R) (paclitaxel protein-bound particles; Abraxis Oncology, Inc.) and Temodar(R) (temozolomide; Schering Plough, Inc.).

Genta Initiates Pilot Clinical Trial of Genasense(R) Plus Abraxane ...  -  Nov 29, 2006
Yahoo! News (press release)Genasense was combined with Abraxane® (paclitaxel protein-bound particles; Abraxis Oncology, Inc.) and Temodar® (temozolomide; Schering Plough, Inc.).

Abraxis BioScience to present data from six studies at San Antonio ...  -  Dec 11, 2006
CNW Telbec (Communiqués de presse),Oral Presentation of Interim Analysis of Randomized, Head-to-Head Phase II Study of ABRAXANE(TM) Versus Taxotere(R) in First-line Metastatic Breast Cancer

Abraxis BioScience to Present Data from Six Studies at San Antonio ...  -  Dec 11, 2006
PharmaLive.com (press release),The studies to be presented are intended to highlight the clinical benefits of ABRAXANE in the treatment of breast cancer. In the oral presentation,

Drug Data Boosts Abraxis Stock  -  Dec 18, 2006
Los Angeles Business Journal (subscription),Shares of Abraxis BioScience Inc. got a good push on Monday after the Los Angeles-based biotech presented weekend data that favorably compared its Abraxane

Market Report -- In Play (ABBI)  -  Dec 25, 2006
MSN MoneyHead-to-head study shows weekly ABRAXANE increased tumor response rate by greater than 60% vs. Taxotere in treatment of metastatic breast cancer Co

Genta begins trial of Genasense  -  Nov 29, 2006
United Press InternationalThe pilot study will evaluate the three-drug combination of Genasense, Abraxis' Abraxane and Schering Plough's Temodar in chemotherapy-naive patients.

Abraxis Wins Approval for Unasyn  -  Nov 28, 2006
Los Angeles Business Journal (subscription),In addition to generics, Abraxis launched its first proprietary drug, a breast cancer treatment called Abraxane, in early 2005.

Analysis: Stopping breast-cancer return  -  Dec 19, 2006
Science Daily (press release)In another study, the use of a new formulation of paclitaxel, branded as Taxol, called nab-paclitaxel -- which is sold under the trade name Abraxane

Understand How Nanotechnology is Revolutionizing Drug Delivery  -  Dec 19, 2006
PharmaLive.com (press release),Abraxane and Doxil are both innovative marketed oncology products utilizing nanotechnology, gaining sales of $184m and $177m in the US and 5 major European

Bevacizumab and Paclitaxel Yield Promising Results in Patients ...  -  Dec 19, 2006
DG News...[Presentation title: Bevacizumab (Avastin) And Albumin Bound Paclitaxel (Abraxane) Treatment In Metastatic Breast Cancer. Abstract 1095]

Pharma Sector: Few Newsmakers Of The Week - Teva, Barr, Genta ...  -  Dec 1, 2006
Trading Markets,...efficacy, pharmacokinetics and pharmacodynamics of Genasense when combined with Abraxis Oncology's Abraxane and Schering Plough's Temodar in patients

Abraxis BioScience Receives FDA Approval for Ampicillin and ...  -  Nov 29, 2006
PipelineReview.com (press release),The first FDA approved product to use this nab platform, ABRAXANE(R), was launched in 2005 for the treatment of metastatic breast cancer.

Abraxis BioScience Receives FDA Approval for Ampicillin and ...  -  Nov 29, 2006
dBusinessNews Los Angeles (press release),The first FDA approved product to use this nab platform, ABRAXANE®, was launched in 2005 for the treatment of metastatic breast cancer.

Abraxis BioScience Receives FDA Approval for Ampicillin and ...  -  Nov 28, 2006
Business Wire (press release),The first FDA approved product to use this nab platform, ABRAXANE ® , was launched in 2005 for the treatment of metastatic breast cancer.

Genasense(R) Shown Active using Intermittent Dosing in Melanoma ...  09 Nov 2006
The use of Genasense plus Abraxane® (paclitaxel protein-bound particles; Abraxis Oncology, Inc.) and Temodar® (temozolomide; Schering Plough, Inc.) also ... -Yahoo! News (press release) (PRN) - AMDL Completes Data for FDA ... [+]  09 Nov 2006
...[+]. (PRN) - Genasense(R) Shown Active using Intermittent Dosing in Melanoma Preclinical Studies and in Combination with Abraxane(R), Temodar(R), and Kinase ... -Bolsamania.com, Gauging Abraxane  Oct 15, 2006
Re ''Hope, at $4,200 a Dose'' (Oct. 1), about the use of our company's drug Abraxane in the treatment of breast cancer: The article ... -Therapeutics Daily (subscription) (press release), Abraxis BioScience Reports Third Quarter 2006 Adjusted Earnings ...  Nov 6, 2006
...“Although the current sales of ABRAXANE do not yet reflect the immense amount of work being done behind the scenes, we remain encouraged by the co-promotion ... -Business Wire (press release), Abraxis Advances  Nov 7, 2006
This is why investors have been so excited about Abraxis BioScience (Nasdaq: ABBI) since the approval of its cancer-treating compound, Abraxane, back in early ... -Motley Fool Abraxis BioScience Posts Q3 Profit - Update  Nov 6, 2006
...company, on Monday reported third quarter profit, compared to a loss last year on higher revenues, partly due to sales of its breast cancer treatment ABRAXANE. ... -Trading Markets, AstraZeneca eyes already marketed drugs  Nov 8, 2006
...(ABBI.O: Quote, Profile, Research) for a breast cancer drug, Abraxane, which Brennan said demonstrated his willingness to bring in marketed medicines. -Reuters Abraxis BioScience Q3 Adj. Earnings Rise; Revenues Up 57% - Quick ...  Nov 6, 2006
...it would conduct an oral presentation at the San Antonio Breast Cancer Symposium regarding data from a Phase 2 randomized study, comparing ABRAXANE to Taxotere ... -Trading Markets, ZIOPHARM Acquires Indibulin Oncology Program from Baxter  Nov 6, 2006
...as compared to marketed taxanes, including paclitaxel (Taxol ® ), paclitaxel protein-bound particles for injectable suspension (Abraxane ® ), and docetaxel ... -Business Wire (press release), ZIOPHARM Acquires Indibulin Oncology Program from Baxter  Nov 6, 2006
...advantages as compared to marketed taxanes, including paclitaxel (Taxol(R)), paclitaxel protein-bound particles for injectable suspension (Abraxane(R)), and ... -PharmaLive.com (press release), Delivering on Nano's Promise  Oct 9, 2006
In addition to Doxil, another liposome-based drug is Abraxane, from Abraxis BioScience Inc., Los Angeles, which was approved last year for metastatic breast ... -Drug Discovery & Development, View Nanobiotechnology’s Contributions to the Pharmaceutical ...  Oct 16, 2006
...solubility, and lower toxicity by nanobiotechnological innovations have been demonstrated for a few existing drugs and FDA approval of Abraxane in January 2005 ... -Nanotechwire.com, Abraxis BioScience Announces Date for Third Quarter Financial ...  Oct 17, 2006
The first FDA approved product to use this nab platform, ABRAXANE ® , was launched in 2005 for the treatment of metastatic breast cancer. ... -Business Wire (press release), Nanotechnology: It's Knocking on FDA's Door  Oct 9, 2006
They include: * Abraxane(R): a treatment for advanced forms of breast cancer using "nanoparticles made of the human protein albumin" * Acticoat(R): uses ... -PR Newswire (press release), Abraxis BioScience to present data from six studies at San Antonio ...  -  Dec 11, 2006
CNW Telbec (Communiqués de presse),Oral Presentation of Interim Analysis of Randomized, Head-to-Head Phase II Study of ABRAXANE(TM) Versus Taxotere(R) in First-line Metastatic Breast Cancer

Genta Initiates Pilot Clinical Trial Of Genasense(R) Plus Abraxane ...  -  Nov 30, 2006
Medical News Today (press release),...was combined with Abraxane(R) (paclitaxel protein-bound particles; Abraxis Oncology, Inc.) and Temodar(R) (temozolomide; Schering Plough, Inc.).

Genta Initiates Pilot Clinical Trial of Genasense(R) Plus Abraxane ...  -  Nov 29, 2006
Yahoo! News (press release)Genasense was combined with Abraxane® (paclitaxel protein-bound particles; Abraxis Oncology, Inc.) and Temodar® (temozolomide; Schering Plough, Inc.).

Genta begins trial of Genasense  -  Nov 29, 2006
United Press InternationalThe pilot study will evaluate the three-drug combination of Genasense, Abraxis' Abraxane and Schering Plough's Temodar in chemotherapy-naive patients.

Abraxis Wins Approval for Unasyn  -  Nov 28, 2006
Los Angeles Business Journal (subscription),In addition to generics, Abraxis launched its first proprietary drug, a breast cancer treatment called Abraxane, in early 2005.

Abraxis BioScience to Present at the Lazard Capital Markets Life ...  -  Nov 21, 2006
PharmaLive.com (press release),The first FDA approved product to use this nab platform, ABRAXANE(R), was launched in 2005 for the treatment of metastatic breast cancer.

Pharma Sector: Few Newsmakers Of The Week - Teva, Barr, Genta ...  -  Dec 1, 2006
Trading Markets,...efficacy, pharmacokinetics and pharmacodynamics of Genasense when combined with Abraxis Oncology's Abraxane and Schering Plough's Temodar in patients

Abraxis BioScience Reports Second Quarter 2006 Adjusted Earnings ...  Aug 3, 2006
ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) revenue increased 87 percent to $36.3 million. ... -Business Wire

Abraxis BioScience Posts Loss In Q2 - Quick Facts  Aug 3, 2006
ABRAXANE revenue increased 87 percent to $36.3 million. ... ABRAXANE sales rose 23% to $66.4 million. Hospital-based sales climbed 23% to $234.2 million. ... -Trading Markets

Tiny Particles Cause a Big Storm for Abraxis  Jul 28, 2006
ABBI) -- over claims that Abraxis had infringed on its patent for nanoparticle formulation by selling the breast cancer treatment, Abraxane -- could have ... -Motley Fool

Cell Therapeutics: Cytotoxic to Shareholders?  Jul 27, 2006
...company, Cell Therapeutics (CTIC) obtains regulatory approval for XYTOTAX (pronounced “Zi-o-taks�), will this pose direct competition to ABRAXANE? ... -Seeking Alpha

Abraxis BioScience Appoints Lisa Gopala as Chief Financial Officer  Aug 3, 2006
The first FDA approved product to use this nab platform, ABRAXANE(R), was launched in 2005 for the treatment of metastatic breast cancer. ... -PharmaLive.com

Abraxis, Bentley, Broadwing, Conseco, MRO: US Equity Movers  Aug 3, 2006
...$23.88. The maker of the Abraxane breast-cancer treatment said second-quarter profit, excluding some items, was 17 cents a share. ... -Bloomberg

Beware the Nano Lawyers  Aug 8, 2006
NYSE: ELN) and Abraxis Biosciences (Nasdaq: ABBI) over a proprietary nanoparticle technology that has led to $134 million in sales of Abraxane, Abraxis' breast ... -Motley Fool

What seemed like a bruise was really a type of cancer  Aug 6, 2006
..."My oncologist did every standard treatment, but he finally put me on a combination of Avastin and Abraxane, a different form of Taxol.". ... -Annapolis Capital

Update - AZ shares dip despite hike in 2Q profits  Jul 28, 2006
It also paid £195 million for a septic shock drug, CytoFab, from Protherics, and bought joint rights to Abraxis Bioscience's Abraxane cancer therapy for £112 ... -Pharma Times (subscription)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional